About PyrAmes & Our Technology

Our Platforms

Presenting Boppli™

Accurate1, non-invasive, continuous, wireless BP monitoring for neonatal and pediatric patients.

Learn More

Presenting Bosimi™

Adult inpatient and emergency care cNIBP.

Learn More

Introducing Bosimi At-Home™

Diagnostics, treatment validation & home medical management.

Learn More

cNIBP Health Impact

PyrAmes platforms will provide options to continuously monitor blood pressure cNIBP for patients of all ages.

Over 50% of NICU Admissions

could benefit from BP monitoring but would not receive an arterial line because it is invasive and costly.2

50% of Adults have High BP

50% of adults are affected by high blood pressure in the US, increasing their mortality rates.3

7.6 Million Deaths Annually

Raised blood pressure (BP) is responsible for 7.6 million deaths worldwide annually.4

cNIBP & Early Detection

cNIBP has the potential for early detection of conditions within preterm infants and adults.

1. Quan, X.; Liu, J.; Roxlo, T.; Siddharth, S.; Leong, W.; Muir, A.; Cheong, S.-M.; Rao, A. Advances in Non-Invasive Blood Pressure Monitoring. Sensors 2021, 21, 4273. https://doi.org/10.3390/s21134273

2. Haidari, E. S., Lee, H. C., Illuzzi, J. L., Phibbs, C. S., Lin, H., & Xu, X. (2020). Hospital variation in admissions to neonatal intensive care units by diagnosis severity and category. Journal of Perinatology, doi:10.1038/s41372-020-00775-z

3. https://www.cdc.gov/bloodpressure/facts.htm

4. https://pubmed.ncbi.nlm.nih.gov/22157565/

News & Updates

January 20, 2022

PyrAmes Technology Featured in Neonatal Intensive Care Journal

The PyrAmes Boppli™ device is featured on page 11 in the Winter 2022 edition of Neonatal Intensive Care: The Journal of Perinatology-Neonatology. The article focuses on how the Boppli is being developed to meet the need for continuous, non-invasive blood pressure monitoring in the neonatal intensive care unit (NICU).

April 20, 2021

PyrAmes Raises $6 Million in Series A Financing

Cupertino, CA, -- (Marketwired - April 20, 2021) – PyrAmes, Inc., a digital healthcare company focused on innovative products for continuous blood pressure monitoring, today announced the completion of a $6 million Series A financing. The investment round was led by GSR Ventures, with co-investments from Keytone Ventures, XTX Ventures and other investors. (more…)

May 18, 2020

FDA Breakthrough Device Designation

PyrAmes Inc. is proud to announce that the FDA has granted Breakthrough Device Designation (BDD) to Boppli™, which fills the unmet need of monitoring the blood pressure of critically ill infants when an invasive arterial catheter cannot be used due to the risk of complications and adverse effects. (more…)

View All News

2020 FDA Breakthrough Device Designation

Founding Member of CDC National Hypertension Control Roundtable

2020 SWPDC Pediatric Device Award, Member of SWPDC

2019 MedTech Innovator Accelerator & 2020 NCC-PDI MedTech Innovator Pediatric Accelerator

Exponential Medicine 2019 One to Watch Award